Articles tagged "Rejection"

2016 American Transplant Congress
Dendritic Cells and Damage-Associated Molecular Patterns in Aging.
M. Seyda, H. Li, G. Liu, M. Quante, H. Uehara, J. Schuitenmaker, A. Elkhal, S. Tullius.
Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Boston.
Recently, it has been shown that Dendritic Cells (DCs) of old organs accelerate graft rejection by orchestrating IL-17A-mediated T cell responses. Moreover, cell-free DNA has…
2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
K. Patel,¹ B. Stephany,² J. Barnes,¹ S. Bauer,¹ M. Spinner.¹
¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…
2016 American Transplant Congress
Antibody-Mediated Rejection in Pancreas Transplantation.
O. Serrano,¹ D. Vock,² E. Finger,¹ R. Kandaswamy,¹ D. Sutherland,¹ T. Dunn.¹
¹Surgery, Univ. of Minnesota, Minneapolis, MN; ²Biostatistics, University of Minnesota, Minneapolis, MN.
PURPOSE: The diagnostic criteria for antibody-mediated rejection (AMR) in pancreas transplantation (PTx) is evolving. The incidence and long-term effect of AMR have not been well-described.…
2016 American Transplant Congress
Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.
Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.
University of Southern California, Los Angeles; University of Utah, Salt Lake City; Barnabas Health, West Orange; Novartis Pharmaceuticals Corporation, East Hanover.
The US92 study determined whether, in de novo renal transplant patients (pts), concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior compared to CellCept®…
2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
¹Department of Medicine, University of Florida, Gainesville, FL; ²Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…
2016 American Transplant Congress
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
Alloreactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute rejection in the initial period after kidney transplantation. Knowledge…
2016 American Transplant Congress
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.
A. Konvalinka,¹ A. Chruscinski,² S. Kim,¹ K. Tinckam,¹ I. Jurisica,³ R. John.⁴
¹Medicine/Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; ²Medicine/Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada; ³Medical Biophysics and Computational Science, University of Toronto, Toronto, ON, Canada; ⁴Pathology, Toronto General Hospital, Toronto, ON, Canada.
PURPOSE: Antibody-mediated rejection (AMR) is caused by antibodies against human leukocyte antigens (HLA) on graft endothelium, and non-HLA antibodies that target endothelial and epithelial proteins.…
2016 American Transplant Congress
Rapid Emergence of CD28^null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.
M. Cortes, S. Laurie, B. Sayed, M. Ford.
Emory Transplant Center, Atlanta, GA.
Numerous studies have implicated donor-reactive memory T cells in mediating costimulation blockade resistant rejection (CoBRR) following treatment with belatacept. In humans, these memory T cells…
2016 American Transplant Congress
Plasma Endothelial Microvesicle Counts Indicate Allograft Rejection Following Kidney Transplantation.
D. Zecher,¹ A. Cumpelik,² B. Ruhland,¹ B. Banas,¹ H. Hopfer,³ M. Dickenmann,⁴ J. Schifferli.²
¹Nephrology, Regensburg University Hospital, Regensburg, Germany; ²Biomedicine, Basel University Hospital, Basel, Switzerland; ³Pathology, Basel University Hospital, Basel, Switzerland; ⁴Nephrology, Basel University Hospital, Basel, Switzerland.
Background: The release of surface-derived microvesicles (MV) is a common phenomenon of cellular activation and occurs specifically as a consequence of terminal complement complex assembly…
2016 American Transplant Congress
Quadruple Induction Regimen with Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.
M. Miura, H. Higashiyama.
Department of Urology and Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Nephrotoxicity of calcineurin inhibitors (CNI) in kidney allografts has been a significant problem even with low exposure regimens. On the other hand, CNI-free regimen…